This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): talniflumate
Description: LOMUCIN has been approved and marketed for almost 20 years in Argentina, and selected other countries (excluding the United States, Europe, and Japan). The effects of talniflumate in blocking hCLCA1 and mucus overproduction were discovered by Genaera scientists, who have received one patent and submitted additional patent applications protecting the novel uses of talniflumate as a mucoregulator.
Deal Structure: LOMUCIN was discovered, developed and marketed as an anti- inflammatory drug by Laboratorios Bago of Buenos Aires, Argentina. Genaera has an exclusive agreement with Laboratorios Bago to develop and commercialize LOMUCIN as a new chemical entity and mucoregulator drug in all major pharmaceutical markets including the United States, Europe, and Japan.
Partners: Laboratorios Bago
Pink Sheet Genaera Shifts Focus From AMD To Obesity
Pink Sheet Trademark Review
Additional information available to subscribers only: